Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 126 East Lincoln Avenue RAHWAY NJ 07065 |
Tel: | N/A |
Website: | https://www.merck.com |
IR: | See website |
Key People | ||
Robert M. Davis Chairman of the Board, President, Chief Executive Officer | Chirfi Guindo Senior Vice President, Chief Marketing Officer - Human Health | Betty D. Larson Chief People Officer |
David M. Williams Executive Vice President, Chief Information and Digital Officer | Jennifer L. Zachary Executive Vice President, General Counsel, Corporate Secretary | Sanat Chattopadhyay Executive Vice President and President - Merck Manufacturing Division |
Richard R. Deluca Executive Vice President, President - Merck Animal Health | Cristal N. Downing Executive Vice President, Chief Communications and Public Affairs Officer | Dean Y. Li Executive Vice President, President - Merck Research Laboratories | Dalton E. Smart Senior Vice President Finance '�� Global Controller |
Business Overview |
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company's Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. It sells these human health pharmaceutical products to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, and health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. The Company's lead candidate, MK-6070, is a T-cell engager targeting delta-like ligand 3 (DLL3), an inhibitory canonical Notch ligand. |
Financial Overview |
For the three months ended 31 March 2024, Merck & Co Inc revenues increased 9% to $15.78B. Net income increased 69% to $4.76B. Revenues reflect Merck Pharmaceutical segment increase of 7% to $15.19B, United States segment increase of 12% to $7.48B, Europe, Middle East and Africa segment increase of 8% to $3.56B. Net income benefited from Other, net - Balancing value increase from $109.5M to $615.5M (income). |
Employees: | 72,000 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $362,247M as of Mar 31, 2024 |
Annual revenue (TTM): | $61,402M as of Mar 31, 2024 |
EBITDA (TTM): | $11,979M as of Mar 31, 2024 |
Net annual income (TTM): | $2,306M as of Mar 31, 2024 |
Free cash flow (TTM): | $3,498M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | $28,600M as of Mar 31, 2024 |
Shares outstanding: | 2,532,806,307 as of Apr 30, 2024 |
Index Membership: | S&P 500, Dow Industry |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |